Androgen receptor (AR), activated by binding to androgens, forms a complex with RUNX2 (presumably associated with CBFB) in the nucleus. AR inhibits transcriptional activity of RUNX2, which may underlie AR-mediated attenuation of bone turnover. RUNX2 may play a tumor suppressor role in prostate cancer (Baniwal et al. 2009).
The complex of RUNX2 and AR is implicated in stimulation of the PSA gene transcription in response to TGF-beta signaling, but further experimental validation is needed (van der Deen et al. 2010).